Glycomine Inc. Alternatives & Competitors
12 companies similar to Glycomine Inc. — We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a...
Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
Waltham, United States
MBX Biosciences, Inc.
Advancing potential breakthrough medicines for endocrine diseases of substantial medical n...
Carmel, United States
medbo KU
medbo überraschend anders
Regensburg, Germany
Entelexo Biotherapeutics
Entelexo has created a novel platform technology for engineering exosomes as a new approac...
Irvine, United States
Track all Glycomine Inc. competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Evox Therapeutics Ltd
Changing the course of CNS disease
Oxford, United Kingdom
Interrupt Biomedical and Engineering Inc.
health technologies for everyone
Istanbul, Turkey
Vico Therapeutics
Our mission is simple… bring innovative RNA modulating therapies to patients with severe,...
Leiden, The Netherlands
Vivet Therapeutics
Vivet Therapeutics develops gene therapy treatments for inherited liver disorders using li...
Paris, France
Beam Therapeutics
Our vision is to provide life-long cures for patients suffering from serious diseases.
Cambridge, United States
Bittylab® LLC
Bittylab, LLC, is a WBE & WOSB-Certified, NY-based MedTech/FemTech start-up addressing inf...
New York, United States
REGENXBIO
Seeking to improve lives through the curative potential of gene therapy.
Rockville, United States
SleepDoctor
SleepDoctor is a teleconsultation and diagnosis platform specialized in sleep disorders.
Paris, France
About Glycomine Inc.
We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
Development of replacement therapies for rare genetic diseases, Clinical trial research and execution, Drug development for PMM2-CDG
Patients with PMM2-CDG, Caregivers and families of PMM2-CDG patients, Healthcare professionals specializing in genetic disorders
Substrate Replacement Therapy, PMM2-CDG, Congenital Disorder Of Glycosylation, Rare Disease, Metabolism, Protein Misfolding, Orphan Drugs, Therapeutic Options, Enzyme Therapy, Drug Development, Cellular Compartments, Medical Need
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Glycomine Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Glycomine Inc. on 9 Jun 2026. The 12 companies listed here were last checked between 11 Jun 2025 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.